On February 2, 2023, in a notice, the Office of the U.S. Trade Representative (USTR) announced a 75-day interim extension for 81 medical-care product exclusions related to the COVID-19 pandemic. The extension is to allow for the review of comments requested in the same notice on whether these exclusions should be extended for up to six months. According to the notice, the exclusions will be evaluated on a case-by-case basis.
Comments are due March 7, 2023.
Details on comment submission can be found in the notice here: